febuxostat + Uralyt-U

A combination therapy consisting of febuxostat, a xanthine oxidase inhibitor, and Uralyt-U (potassium sodium hydrogen citrate), a urinary alkalinizing agent. This combination is utilized to manage hyperuricemia and dissolve or prevent uric acid stones. Febuxostat works by inhibiting the enzyme xanthine oxidase, thereby reducing the production of uric acid in the body. Uralyt-U increases the pH of the urine to a target range of 6.2–6.9, which significantly enhances the solubility of uric acid, preventing its crystallization into stones and promoting the dissolution of existing calculi. This specific regimen is being evaluated in clinical trials (such as NCT04352153) sponsored by Ai Peng for male patients with comorbid hyperuricemia and nephrolithiasis.

Brand names

Uralyt-U

Other names

potassium sodium hydrogen citratepotassium citratesodium citratecitric acidfebuxostat